Skip to search formSkip to main contentSkip to account menu

GW776C85

Known as: 776C85 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

eniluracil

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Advances in Brief Attenuation of the Antitumor Activity of 5-FluorouraciI by ( R )-5-Fluoro-5 , 6-dihydrouracil
5-Ethynyluracil (5-EU; 776C85) is a potent mechanism-based inactivator of dihydropyrimidine dehydrogenase that improves the… 
1998
1998
Improving 5-FU with a novel dihydropyrimidine dehydrogenase inactivator.
GW776C85 is a new drug that has been shown to be an effective inactivator of dihydropyrimidine dehydrogenase (DPD). Preclinical… 
1996
1996
Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics: allometric scaling of animal data, pharmacokinetics and toxicodynamics of 5-fluorouracil in humans
Abstract The pharmacokinetics of 5-fluorouracil (5-FU) in different animal species treated with the dihy-dropyrimidine… 
1995
1995
5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil.
We studied the effects of 5-ethynyluracil (776C85 and 776C), a potent mechanism-based inactivator of dihydropyrimidine… 
1994
1994
5-Ethynyluracil (776C85): protection from 5-fluorouracil-induced neurotoxicity in dogs.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)